Tag: FDA Orphan Drug Designation
BiVictriX Therapeutics receives FDA orphan drug designation for BVX001 in AML
BiVictriX Therapeutics plc (AIM: BVX), a prominent UK-based biotechnology firm, has reached a pivotal regulatory milestone as the US Food and Drug Administration (FDA) has ... Read More
Poseida Therapeutics gets FDA orphan drug designation for P-BCMA-ALLO1 in multiple myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a trailblazer in the field of clinical-stage cell and gene therapy, has achieved a significant milestone with the U.S. Food ... Read More